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Abstract. Oxidoreductase protein disulphide isomerases (PDI) 
are involved in the regulation of a variety of biological processes 
including the modulation of endoplasmic reticulum (ER) stress, 
unfolded protein response (UPR), ER-mitochondria commu-
nication and the balance between pro-survival and pro-death 
pathways. In the current study the role of the PDIA1 family 
member in breast carcinogenesis was investigated by measuring 
ROS generation, mitochondrial membrane disruption, ATP 
production and HLA-G protein levels on the surface of the cellular 
membrane in the presence or absence of PDIA1. The results 
showed that this enzyme exerted pro-apoptotic effects in estrogen 
receptor (ERα)-positive breast cancer MCF-7 and pro-survival in 
triple negative breast cancer (TNBC) MDA-MB-231 cells. ATP 
generation was upregulated in PDIA1-silenced MCF-7 cells 
and downregulated in PDIA1-silenced MDA-MB-231 cells in 
a manner dependent on the cellular redox status. Furthermore, 
MCF-7 and MDA-MB-231 cells in the presence of PDIA1 
expressed higher surface levels of the non-classical human 
leukocyte antigen (HLA-G) under oxidative stress conditions. 
Evaluation of the METABRIC datasets showed that low PDIA1 
and high HLA‑G mRNA expression levels correlated with 
longer survival in both ERα-positive and ERα-negative stage 2 
breast cancer patients. In addition, analysis of the PDIA1 vs. the 
HLA‑G mRNA ratio in the subgroup of the living stage 2 breast 
cancer patients exhibiting low PDIA1 and high HLA-G mRNA 
levels revealed that the longer the survival time of the ratio was 
high PDIA1 and low HLA‑G mRNA and occurred predomi-
nantly in ERα-positive breast cancer patients whereas in the 
same subgroup of the ERα-negative breast cancer mainly this 
ratio was low PDIA1 and high HLA‑G mRNA. Taken together 
these results provide evidence supporting the view that PDIA1 is 
linked to several hallmarks of breast cancer pathways including 
the process of antigen processing and presentation and tumor 
immunorecognition. 
Introduction
The fine‑tuning of the intracellular levels of reactive oxygen 
species (ROS) and the cellular redox state is of crucial 
importance for breast carcinogenesis, progression, prognosis 
and therapy (1). ROS are involved in multiple redox regulated 
signaling pathways including the modulation of endoplasmic 
reticulum and mitochondria homeostasis and contribute to 
the pathogenesis of a number of human diseases including 
breast cancer (2). Cancer cells generate persistently high ROS 
levels which activate pro-survival mechanisms including 
endoplasmic reticulum (ER) stress, unfolded protein response 
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(UPR) and inhibition of pro-apoptotic pathways initiated 
in mitochondria (1,3). ER stress is activated when the ER 
chaperones involved in the refolding of misfolded proteins 
are not functional leading to the accumulation of high levels 
of misfolded proteins in the cell and subsequent induction of 
UPR (4). By activating ER stress, the cells transiently halt 
protein synthesis in order to cope with the accumulation 
of non-functional proteins but if the concentration of the 
misfolded proteins is high the UPR stimulates cell death (5,6). 
Redox responsive endoplasmic reticulum proteins such 
as members of the protein disulfide isomerase (PDI) super-
family and in particular the prototype family member prolyl 
4-hydroxylase subunit beta (P4HB or PDIA1) activates the 
ER transmembrane kinase protein kinase R (PKR)-like endo-
plasmic reticulum kinase (PERK) thus playing a crucial role 
in the stimulation of the UPR (7). PDIA1 has been shown to 
modulate cellular oxidative stress mediating homeostasis of 
the antioxidant glutathione (8) and its function is regulated by 
cellular redox state. Specifically, PDIA1 exerts chaperone and 
isomerase activities in an oxidative stress-dependent manner 
facilitating redox-mediated regulation of protein folding (9-12). 
PDIA1 is primarily localized in the endoplasmic reticulum 
but extracellular matrix, mitochondria, nucleus, and cytosolic 
PDIA1 localization has also been demonstrated (13). Diverse 
subcellular localization confers PDIA1 a dual role in cell 
death and survival during ER stress (14). For instance, PDIA1 
mitochondrial localization contributes to the induction of 
mitochondrial outer membrane permeabilization (MOMP), the 
release of the mitochondrial cytochrome c into the cytoplasm 
and the initiation of apoptosis (15). Furthermore, PDIA1 mito-
chondrial localization suggested that this protein is involved 
in the regulation of redox mediated mitochondrial functions 
including energy metabolism (16). Nuclear localization of 
PDIA1 implicated this protein in the regulation of the activity 
of redox‑sensitive transcription factors to co‑ordinate efficient 
ROS detoxification (17). Extracellular matrix localization of 
PDIA1 was potentially related to invasion and metastasis as 
it has been shown for PDI family members in glioma (18) and 
hepatocarcinoma (14). 
The impact of ER stress on immune responses (19) as well 
as the involvement of the UPR in the regulation of the tumor 
microenvironment are becoming widely acknowledged (20). 
PDI family members are key components of the antigen 
presentation machinery (21,22) contributing to the selection 
and loading of the optimal antigen to MHC class I mole-
cules (23,24) and the dissociation of the antigen-loaded MHC 
class I complex and exit from the endoplasmic reticulum (25). 
In the present study, the regulation of the PDIA1 functions 
under diverse oxidative stress conditions and its role in a range 
of physiological processes known to affect breast carcinogen-
esis were investigated in the estrogen receptor (ERα)-positive 
MCF-7 and the triple negative MDA-MB-231 breast cancer 
cells. The correlation between PDIA1 and HLA‑G mRNA 
levels and their association with the overall survival were 
also investigated in breast cancer patients by analyzing the 
molecular taxonomy of breast cancer international consortium 
(METABRIC) microarray dataset available in the cBio cancer 
genomics portal (http://cbioportal.org) (26).
The results provide evidence to support the view that 
PDIA1 differentially affects antioxidant homeostasis and ATP 
generation in the ERα-positive vs. the TNBC cells and its 
mRNA levels are linked to the overall survival of stage 2 breast 
cancer patients. The findings of this study indicate an alterna-
tive molecular mechanism directing the evasion of immune 
surveillance in breast tumors that could be used as a platform 
for the design of stratified breast cancer immunotherapies, in 
addition to those that use PDIA1 as a therapeutic target (27).
Materials and methods
Cell culture. The human breast carcinoma cell lines MCF-7 
(expressing wild-type p53) and MDA-MB-231 [bearing 
mutated p53 (R280K)] were obtained from the European 
collection of cell cultures (ECACC) and maintained in 
Dulbecco's modified Eagle's medium (Sigma‑Aldrich, UK) 
supplemented with 10% foetal bovine serum (Gibco) and 
1% penicillin/streptomycin (Lonza) at 37˚C in a humidified 
atmosphere containing 5% CO2 until they reached 70% conflu-
ency (48 h). Where indicated cells were treated with 10 ng/ml 
interferon-γ (IFN-γ) (Sigma-Aldrich) for 24 h or 10 µM etopo-
side (ETOP) for 24 h (Sigma-Aldrich).
Western blotting. Cellular extracts from MCF-7 and 
MDA-MB-231 were collected in ice-cold TNN buffer containing 
1 mM DTT, 1 mM PMSF, and 1 µg/ml protease inhibitors. 
Protein concentrations were determined by the Bradford 
assay (Sigma Aldrich) and 30 µg of protein per sample were 
resolved on a 20% precast polyacrylamide gel and transferred 
to a PVDF membrane. The membranes were blocked using 5% 
fat‑free milk in PBS (v/v) for 1 h at 25˚C. Membranes were 
then incubated in 2.5% milk in PBS-0.1% Tween-20 (v/v) with 
anti-P4HB antibody (Santa Cruz Biotechnology; sc-136230) 
(dilution 1:500) or β-actin (Sigma Aldrich; A1978) (dilution 
1:10,000) overnight at 4˚C. The membranes were washed 
three times with PBS-0.1% Tween-20 (v/v) for 5 min and then 
incubated with secondary anti-mouse immunoglobulin G 
conjugated to horsedish peroxidase (GE Healthcare) (dilution 
1:1,000) in 2.5% milk in PBS-0.1% Tween-20 (v/v) for 1 h at 
25˚C. Protein bands were then visualized using the ChemiDoc 
MP imaging system (Bio-Rad).
siRNA transfection. A concentration of 5 µM of the 
siGENOME P4HB siRNA and 5 µM of the siGENOME 
non-targeting siRNA pool was added to each well containing 
2x105 cells in DMEM and incubated for 72 h according to 
the suppliers' instructions (Dharmacon) as described previ-
ously (28). Immediately after the 72 h transfection cells were 
used for subsequent experimentation. The sequences of the 
siRNA pools against P4HB and scramble siRNA were: P4HB: 
ACA GGA CGG UCA UUG AUU A, GGA CGG UCA UUG AUU 
ACA A, CCA AGA GUG UGU CUG ACU A, CAG AGA GGA 
UCA CAG AGU U and scramble: UAG CGA CUA AAC ACA 
UCA A, UAA GGC UAU GAA GAG AUA C, AUG UAU UGG 
CCU GUA UUA G, AUG AAC GUG AAU UGC UCA A.
Intracellular ROS generation. ROS generation was measured 
using the dye CM-H2DCF‑DA (29). Briefly, cells were grown 
in 6-well plates at a density of 1x106 cells/well and treated 
as indicated. Cells were centrifuged for 3 min at 400 x g at 
25˚C, the supernatant was removed and the pellet resuspended 
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in cold PBS. Then, 1 µM of CM-H2DCF-DA was added 
and the extracts were incubated for 30 min in the dark at 
25˚C. Subsequently, 30 µl of samples were transferred to 
A2 slides (ChemoMetec) and ROS were measured using the 
NucleoCounter NC-3000™ (ChemoMetec). 
Glutathione cellular levels. The NucleoCounter NC-3000™ 
system was used to detect changes in the intracellular level 
of (reduced) thiols. Following the indicated treatments cells 
were dissociated from the culture plates using 500 µl disso-
ciation buffer (ChemoMetec). Then the cells were stained 
with solution 5 according to the manufacturer's instructions 
(ChemoMetec), loaded onto 8-chamber NC-slides and samples 
were analysed using the NucleoCounter NC-3,000™.
Mitochondrial membrane disruption. Mitochondrial trans-
membrane disruption was measured using the cationic dye 
JC-1 (5,5,6,6-tetrachloro-1,1,3,3-tetraethyl benzimidazol 
carbocyanine iodide) (ChemoMetec) and the NucleoCounter 
NC-3,000™. Following the indicated treatment, the cells 
were stained with JC-1 and DAPI according to the manufac-
turer's instructions (ChemoMetec). Cellular JC-1 monomers 
and aggregates were detected as green and red fluorescence, 
respectively. Mitochondrial depolarization and apoptosis were 
revealed as a decrease in the ratio of red/green fluorescence. 
Staining with the blue fluorescent dye (DAPI) was used to 
detect necrotic and late apoptotic cells. After stained cells 
were loaded on an 8-chamber NC-Slide A8™ and samples 
were analysed quantifying the amount of blue, green, and red 
fluorescence using the NucleoCounter NC‑3,000™.
Adenosine triphosphate assay. ATP levels were measured 
using the ViaLight plus kit (Lonza), based on the amount 
of bioluminescent ATP generated in cells. ATP monitoring 
reagent (AMR plus) was prepared by adding assay buffer 
into the vial containing the lyophilized AMR and incubated 
at room temperature for 15 min for complete rehydration. 
Cells were lysed in 50 µl and the cell lysate was added to a 
luminometer plate together with 100 µl of cell lysis reagent 
for 10 min. A total volume of 100 µl of AMR plus was added 
to the appropriate well. The plate was then incubated at room 
temperature for 2 min and luminescence values were obtained 
using the Fluostar OPTIMA microplate reader (BMG Labtech).
HLA‑G surface levels. Breast cancer cell lines were seeded 
in a 6-well plate at a concentration of 1x106 cancer cells/well 
for 24 h in a CO2 incubator. Cells were then transfected with 
P4HB siRNA or scramble siRNA for 48 h at 37˚C. Following 
treatment with IFN-γ or ETOP for 24 h at 37˚C, the cells were 
detached from the wells with 500 µl dissociation buffer and 
the cell lysates were transferred to a 15 ml falcon tube and 
centrifuged at 300 x g for 5 min at 4˚C. The supernatant was 
removed and 3x105 cells in 100 µl (10% FBS in PBS) were 
transferred to a fresh tube. APC-anti human HLA-G (Thermo 
Fisher) was added and the cells were incubated for 30 min on 
ice in the dark. The stained samples were analysed by flow 
cytometry (Becton Dickinson).
PDIA1‑HLA‑G correlation in breast cancer patients. The 
METABRIC breast cancer dataset was downloaded from 
cBio Cancer Genomics Portal (http://cbioportal.org) for 1,900 
breast cancer patients (26). The distribution of the mRNA 
expression levels of PDIA1 and HLA‑G was measured across 
samples. PDIA1 (P4HB) and HLA‑G mRNA expression 
levels were considered high if their z-scores were higher 
or equal to the 75th percentile of the distribution (30) and 
low if their z-scores were lower than the 75th percentile of 
the distribution (z-score high PDIA ≥ 0.572, z‑score high 
HLA‑G≥ 0.517).
Statistical analysis. Graphs were plotted using GraphPad 
PRISM 7 (GraphPad software Inc.). The Mann-Whitney test 
was used to assess the significance of the difference between 
two groups, whereas the Kruskal-Wallis test was used to 
assess the significance of the differences between more than 
two groups. Log-rank was used to test the significance of 
the difference between Kaplan-Meier survival curves. The 
mean was calculated as ± SEM. P<0.05 indicated statistical 
significance.
Results
Silencing of PDIA1 gene expression in breast cancer cells. To 
investigate the role of the PDIA1 in the modulation of diverse 
hallmarks of cancer such as resistance to cell death, regulation 
of cellular energy production pathways and evasion of immune 
destruction, the gene expression of this oxidoreductase was 
silenced in the ERα-positive (MCF-7) and the ERα-negative 
(MDA‑MB‑231) breast cancer cells. The efficiency of silencing 
of the PDIA1 gene expression was confirmed for each assay 
performed. The representative western blot analysis shown in 
Fig. 1, which shows the efficient silencing of the PDIA1 gene 
expression only in MCF-7 and MDA-MD-231 cells transfected 
with the siRNA-PDIA1 untreated or treated with IFN-γ or 
ETOP, but not in those cells transfected with the scramble 
siRNA.
PDIA1 modulates ROS generation in breast cancer cells. 
Type II interferon IFN-γ induces both carcinogenic and cyto-
toxic effects (31) playing an important role in cell growth and 
survival in a manner involving the generation of ROS (32). 
The topoisomerase II inhibitor ETOP has also been shown to 
induce ROS generation in brain cancer cells (33). Additionally, 
IFN-γ regulates the expression of genes encoding NADPH 
oxidases (Nox) (34) and evidence indicating functional interac-
tion between PDI and Nox family members (35) suggests that 
IFN-γ may indirectly regulate PDIA1 levels and activity under 
diverse oxidative stress conditions. The association between 
overexpression of NADPH oxidases and resistance to ETOP 
treatment as a result of ROS-mediated induction of senescence 
has also been reported (36), suggesting that PDIA1 is a poten-
tial indirect modulator of ROS mediated effects exerted upon 
ETOP treatment. To investigate the potential involvement of 
PDIA1 in altering the IFN-γ and ETOP mediated redox state 
in breast cancer cells ROS levels were measured in MCF-7 
and MDA-MB-231 cells treated with these compounds in the 
presence or absence of PDIA1. 
In MCF-7 cells silencing of PDIA1 did not affect ROS 
generation in the untreated or IFN-γ treated cells compared 
to scramble-transfected cells (Fig. 2A, compare bars 1 and 3 
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to bars 2 and 4, respectively). Decreased ROS levels were 
recorded in PDIA1-silenced MCF-7 cells treated with ETOP 
compared to scramble-transfected cells under the same 
conditions (Fig. 2A, compare bar 5 to bar 6). Decreased ROS 
levels were measured in MCF-7 cells treated with IFN-γ 
in the presence of PDIA1 compared to the untreated cells 
(Fig. 2A, compare bar 3 to bar 1) whereas in the presence of 
PDIA1 ETOP did not affect ROS generation in MCF-7 cells 
(Fig. 2A compare bar 5 to bar 1). In the absence of PDIA1 
significantly decreased ROS generation was observed in 
the ETOP-treated MCF-7 cells compared to untreated 
cells (Fig. 2A, compare bar 6 to bar 2). Significantly 
increased ROS levels were observed in PDIA1-silenced 
MDA-MB-231 cells treated with either IFN-γ or ETOP 
compared to the scramble-transfected cells under the same 
conditions (Fig. 2C, compare bars 3 and 5 to bars 4 and 6, 
respectively). Significantly decreased ROS levels were 
observed in the IFN-γ treated MDA-MB-231 cells in the 
presence of PDIA1 compared to untreated cells under the 
same conditions (Fig. 2C, compare bar 3 to bar 1). ETOP 
treatment of PDIA1-silenced MDA-MB-231 cells resulted 
in a significant increase of ROS generation compared to 
untreated cells (Fig. 2C, compare bar 6 to bar 2). PDIA1 
protein levels were not significantly affected by any treat-
ment (Fig. 1). Representative histograms showing the ROS 
levels in scramble or siRNA-PDIA1-transfected MCF-7 
or MDA-MB-231 cells untreated or treated with IFN-γ or 
ETOP are provided in Fig. 2B and 2D, respectively.
PDIA1 regulates GSH levels in breast cancer cells. The 
ratio of glutathione (GSH) vs. glutathione disulfide (GSSG) 
is important for cellular physiology since a decreased 
GSH/GSSG ratio leads to increased susceptibility to oxida-
tive stress whereas increased GSH levels induce resistance 
of cancer cells to oxidative stress (37). Inhibition of PDIA1 
isomerase activity has been shown to abrogate glutathione 
depletion (8) indicating the essential role of PDIA1 in 
the process of disulfide bond formation and therefore the 
regulation of the ratio of GSH vs. GSSG (38). To investigate 
the role of PDIA1 in the regulation of the GSH homeostasis 
in breast cancer cells the GSH/GSSG ratio was investigated 
in MCF-7 and MDA-MB-231 cells in which the PDIA1 
expression had been silenced.
Significant upregulation of GSH levels was observed 
in the untreated PDIA1-silenced MCF-7 cells compared 
to scramble-transfected cells under the same conditions 
(Fig. 3A, compare bar 1 to bar 2). There were no other changes 
evident in GSH levels in MCF-7 cells in any of the conditions 
studied (Fig. 3A). By contrast, in the MDA-MB-231 cells 
significant downregulation of GSH levels was observed in 
the untreated PDIA1-silenced MDA-MB-231 cells compared 
to the untreated and scramble-transfected cells (Fig. 3C, 
compare bar 1 to bar 2). Downregulation of GSH levels was 
also recorded in the ETOP-treated MDA-MB-231 cells in the 
presence of PDIA1 compared to the untreated cells (Fig. 3C, 
compare 5 to bar 1). Finally upregulated GSH levels were 
measured in PDIA1 silenced MDA-MB-231 cells treated with 
IFN-γ compared to the siRNA-PDIA1 transfected untreated 
cells (Fig. 3C, compare bar 4 to bar 2). Representative histo-
grams showing the GSH levels in scramble or siRNA-PDIA1 
transfected MCF-7 or MDA-MB-231 are provided in 
Fig. 3B and 3D respectively.
PDIA1 regulates mitochondrial function in breast cancer 
cells. The communication between ER and mitochondria is 
critical for several important cellular functions including the 
balance between survival and death (39). The role of PDIA1 in 
the regulation of this communication has been shown in cells 
in which blocking the PDIA1 activity prevents stimulation of 
the mitochondrial outer membrane potential (MOMP) and 
inhibits apoptosis (15). In addition, the combination of ETOP 
with a PDI inhibitor has been shown to trigger increased 
ER-associated calcium influx and loss of mitochondrial 
membrane integrity (40). These findings led us to investigate 
the effect of PDIA1 on the integrity of the mitochondrial 
membrane of breast cancer cells.
Figure 1. Silencing of PDIA1 gene expression in breast cancer cells. MCF-7 (A) and MDA-MD-231 (B) cells were transfected with either scramble or 
siRNA-PDAI1 and treated with DMSO, IFN-γ or ETOP as indicated. The silencing efficiency was evaluated using western blot analysis. 
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The mitochondrial membrane potential was investigated 
in MCF-7 and MDA-MB-231 cells in which the PDIA1 
expression had been silenced and cells were left untreated or 
treated with IFN-γ or ETOP. Silencing of PDIA1 in MCF-7 
cells downregulated mitochondrial membrane potential in the 
untreated cells compared to the scramble-transfected cells 
under the same conditions (Fig. 4A, compare bar 1 to bar 2). 
Increased mitochondrial membrane potential was observed 
in the presence of PDIA1 in MCF-7 cells treated with IFN-γ 
compared to the untreated cells (Fig. 4A, compare bar 3 to 
bar 1), whereas decreased mitochondrial membrane disruption 
was measured in the presence of PDIA1 in MCF-7 cells treated 
with ETOP compared to the untreated cells (Fig. 4A, compare 
bar 5 to bar 1). PDIA1-silenced MCF-7 cells treated with IFN-γ 
exhibited increased mitochondrial membrane disruption 
compared to PDIA1-silenced untreated cells (Fig. 4A, 
compare bar 4 to bar 2). Silencing of PDIA1 in MDA-MB-231 
cells upregulated mitochondrial membrane disruption in 
ETOP-treated cells compared to the scramble-transfected cells 
under the same conditions (Fig. 4C, compare bar 5 to bar 6). 
Increased mitochondrial membrane disruption levels were also 
measured in MDA-MB-231 cells treated with IFN-γ in the 
presence of PDIA1 compared to the untreated cells (Fig. 4C, 
compare bar 3 to bar 1). In ETOP-treated PDIA1-silenced 
MDA-MB-231 cells the mitochondrial membrane disruption 
was upregulated compared to the untreated cells under these 
conditions (Fig. 4C, compare bar 6 to bar 2). Representative 
histograms showing the intensity of JC-1 (%) in scramble or 
siRNA targeting PDIA1-transfected MCF-7 and MDA-MB-231 
cells are provided in Fig. 4B and 4D, respectively.
PDIA1 modulates energy metabolism in breast cancer cells. 
The communication between ER and mitochondria by a 
network of proteins residing in the interface between the two 
organelles is critical in controlling vital physiological func-
tions including energy metabolism and cellular death/survival 
decisions (41). Structural and functional changes of the 
ER-mitochondria contact proteins result in the deregulation of 
calcium (Ca2+) homeostasis and consequently mitochondrial 
energy production and cell death (42). PDI plays an important 
Figure 2. ROS generation in untreated, IFN-γ or ETOP treated breast cancer cells in the presence or absence of PDIA1. (A and C) Bar chart represent the ROS 
levels in siRNA scramble transfected (black bars) or siRNA-PDIA1 transfected (white bars) MCF-7 (A) or MDA-MB-231 (C) cells untreated or treated with 
either IFN-γ or ETOP as indicated. ROS levels recorded in the scramble transfected and untreated cells were arbitrarily set to 100 and the different treatments 
were calculated accordingly. The asterisks above each bar indicate the statistical significance of the comparison between bars 3 and 5 compared to bar 1 and 
bars 4 and 6 compared to bar 2. The asterisks above the line indicate the comparison between black and white bars. (B and D) Representative histograms 
showing the ROS levels in scramble or siRNA-PDIA1 transfected MCF-7 (B) or MDA-MB-231 (D) cells untreated or treated with IFN-γ or ETOP. The data 
represent the mean of three independent experiments and the error bars the mean ± SEM. *P<0.05, **P<0.01 and ***P<0.005. 
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role in the cross talk between cellular redox state and Ca2+ 
homeostasis in the ER (43) suggesting its involvement in the 
regulation of energy metabolism (44).
To test this hypothesis ATP production was investigated in 
MCF-7 and MDA-MB-231 cells treated with IFN-γ or ETOP in 
the presence or absence of PDIA1 (Fig. 5). Silencing of PDIA1 
in MCF-7 cells upregulated ATP levels in the untreated cells 
(Fig. 5A, compare bar 1 to bar 2). Decreased ATP levels were 
recorded in MCF-7 cells treated with IFN-γ or ETOP in the pres-
ence of PDIA1 compared to the untreated cells (Fig. 5A, compare 
bars 3 and 5 to bar 1). Decreased ATP levels were also observed 
in PDIA1-silenced MCF-7 cells treated with IFN-γ (Fig. 5A, 
compare bar 3 to bar 4) or ETOP compared to scramble-trans-
fected cells under the same conditions (Fig. 5A, compare bar 5 to 
bar 6). Overall, no significant changes in ATP levels were evident 
in untreated, IFN-γ- or ETOP-treated PDIA1-silenced MCF-7 
cells compared to those measured in the untreated, IFN-γ or 
ETOP treated cells in the presence of PDIA1 (Fig. 5B)
Decreased ATP levels were measured in MDA-MB-231 cells 
treated with IFN-γ or ETOP in the presence of PDIA1 
compared to the untreated cells (Fig. 5C, compare bars 3 and 
5 to bar 1). Silencing of PDIA1 in MDA-MB-231 cells down-
regulated ATP levels in the untreated cells (Fig. 5C, compare 
bar 1 to bar 2), IFN-γ-treated cells (Fig. 5C, compare bar 3 
to bar 4), and ETOP-treated cells (Fig. 5C, compare bar 5 to 
bar 6). ATP generation was downregulated significantly in 
untreated, IFN-γ- or ETOP-treated MDA-MB-231 cells in the 
absence of PDIA1 vs. the presence of PDIA1 (Fig. 5D).
PDIA1 modulates HLA‑G surface levels in breast cancer cells. 
In recent years, the connection between ER stress signalling 
pathways, UPR induction, deregulation of energy metabo-
lism, and immune responses has been unravelled (45,46). 
The link between the cellular redox state with several 
ER-resident chaperones and in particular PDIA1 in mediating 
the processing, optimal selection and antigen loading to the 
MHC class I during the process of antigen presentation have 
been demonstrated (23,24,47). Apart from the peptide antigen 
processing, loading and stabilization of the early MHC class 
I complex (22), PDIA1 has also been shown to modulate the 
Figure 3. GSH levels in untreated, IFN-γ or ETOP treated breast cancer cells in the presence or absence of PDIA1. (A and C) Bar charts represent GSH levels 
in MCF-7 (A) and MDA-MD-231 (C) cells in the presence (black bars) or absence of PDIA1 (white bars) untreated or treated with IFN-γ or ETOP as indicated. 
GSH levels detected in the scramble transfected and untreated cells were arbitrarily set to 100 and the different treatments were calculated accordingly. The 
asterisks above each bar indicate the statistical significance of the comparison between bars 3 and 5 compared to bar 1 and bars 4 and 6 compared to bar 2. 
The asterisks above the line indicate the comparison between black and white bars. (B and D) Representative histograms showing the GSH levels in siRNA 
scramble or PDIA1 transfected MCF-7 (B) or MDA-MB-231 (D) cells. The data represent the mean of three independent experiments and the error bars the 
mean ± SEM. *P<0.05 and **P<0.01. 
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MHC class I expression (48). Two types of the MHC class I 
molecules have been described; the classical (human leukocyte 
antigen HLA-A, HLA-B, and HLA-C alleles) and the 
non-classical (HLA-E, HLA-F, HLA-G) proteins (49). Human 
breast cancer tissues and breast cancer cells express HLA-G 
whereas in normal epithelial mammary cells HLA-G mRNA 
expression has not been detected indicating the involvement 
of the non-classical MHC class I molecules in the evasion 
of the immune surveillance by breast cancer cells and their 
important role in determining the prognosis of breast cancer 
patients (50-52).
To investigate any potential role of PDIA1 in modulating 
the surface expression of the non-classical MHC class I 
HLA-G molecule and thus in the process of evasion of immune 
surveillance (51,52) the HLA-G surface levels were followed 
in untreated MCF-7 and MDA-MB-231 cells or treated with 
IFN-γ or ETOP in the presence or absence of PDIA1 (Fig. 6). 
Significantly lower HLA‑G surface levels were observed in 
both MCF-7 and MDA-MB-231 cells in the absence of PDIA1 
compared to MCF-7 and MDA-MB-231 cells in the presence 
of PDIA1 (Fig. 6A and B).
PDIA1/HLA‑G mRNA ratio correlates with overall survival 
in breast cancer patients. To explore the correlation between 
PDIA1 and HLA‑G gene expression and identify any potential 
clinical implications of the PDIA1 and HLA‑G ratio in breast 
cancer patient data obtained from the METABRIC dataset avail-
able in the cBio Cancer Genomics Portal (http://cbioportal.org) 
(26) were analyzed to follow the PDIA1 and HLA‑G mRNA 
levels in various stages of ERα-positive and ERα-negative 
breast cancer patients. Table I indicates the number of 
ERα-positive and ERα-negative patients and the stage clas-
sification of their disease. Results shown in Fig. S1 indicate the 
PDIA1 and HLA‑G mRNA expression levels in ERα-positive 
(Fig. S1A and B) and ERα-negative (Fig. S1C and D) patients 
in each stage of the disease. The correlation between PDIA1 
and HLA‑G mRNA levels in ERα-positive stage 1 (Fig. S2A), 
stage 2 (Fig. S2B) and stage 3 (Fig. S2C) patients indicates 
Figure 4. Mitochondrial membrane potential in untreated, IFN-γ or ETOP-treated breast cancer cells in the presence or absence of PDIA1. (A and C) Bar charts 
represent the mitochondrial membrane disruption levels in siRNA scramble transfected (black bars) or siRNA-PDIA1 transfected (white bars) MCF7 (A) and 
MDA-MB-231 (C) cells untreated or treated with IFN-γ or ETOP as indicated. The mitochondrial membrane disruption levels in the scramble transfected and 
untreated cells were arbitrarily set to 100 and the different treatments were calculated accordingly. The asterisks above each bar indicate the statistical signifi-
cance of the comparison between bars 3 and 5 compared to bar 1 and bars 4 and 6 compared to bar 2. The asterisks above the line indicate the comparison 
between black and white bars. (B and D) Representative histograms showing the JC-1 (%) intensity in scramble siRNA or siRNA targeting PDIA1 transfected 
MCF-7 (B) and MDA-MB-231 (D) cells. The data represent the mean of three independent experiments and the error bars the mean ± SEM. *P<0.05, **P<0.01, 
***P<0.005 and ****P<0.001. 
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statistically significant results for stage 2 and 3 patients. A 
similar analysis of the correlation between PDIA1 and HLA‑G 
mRNA levels in ERα-negative stage 1 (Fig. S2D), stage 2 
(Fig. S2E) and stage 3 (Fig. S2F) patients did not show any 
statistical significance. Kaplan-Meir survival curves were 
plotted to explore whether the PDIA1/HLA‑G mRNA ratio 
was associated with the overall survival of stage 2 breast 
cancer patients (Fig. 7). Statistically significant association 
Figure 6. HLA-G levels in untreated, IFN-γ or ETOP-treated breast cancer cells in the presence or absence of PDIA1. Bar charts represent the cell surface 
HLA-G levels in siRNA scramble transfected or siRNA PDIA1 transfected MCF-7 (A) and MDA-MB-231 (B) cells. The data represent the mean of three 
independent experiments and the error bars the mean ± SEM. *P<0.05 and **P<0.01. 
Figure 5. ATP levels in untreated, IFN-γ or ETOP-treated breast cancer cells in the presence or absence of PDIA1. (A and C) Bar charts represent the ATP 
generation in scramble transfected (black bars) or siRNA PDIA1 transfected (white bars) MCF-7 (A) and MDA-MB-231 (C) cells untreated (bars 1 and 2) or 
treated with either IFN-γ (bars 3 and 4) or ETOP (bars 5 and 6). ATP generation levels in the untreated control were arbitrarily set to 100 and the different 
treatments were calculated accordingly. The asterisks above each bar indicate the statistical significance of the comparison between bars 3 and 5 compared to 
bar 1 and bars 4 and 6 compared to bar 2. The asterisks above the line indicate the comparison between black and white bars. (B and D) Bar charts represent 
the average ATP generation levels in the non-treated, IFN-γ and ETOP treated MCF-7 (B) and MDA-MB-231 (D) cells in the presence (scramble siRNA) or 
absence (PDIA1 siRNA) of PDIA1. The data represent the mean of three independent experiments and the error bars the mean ± SEM. **P<0.01, ***P<0.005 
and ****P<0.0001.
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between low PDIA1/high HLA-G mRNA ratio and longer 
overall survival was observed in ERα-negative stage 2 patients 
(Fig. 7D). Analysis of the subgroup of the living breast cancer 
patients at stage 2 exhibited low PDIA1 and high HLA-G 
mRNA ratio indicated that in the ERα-positive patients longer 
survival is associated predominantly with high PDIA1 and low 
HLA-G mRNA levels (Fig. 7B) whereas in the ERα-negative 
patients longer survival is associated mainly with low PDIA1 
and high HLA‑G mRNA levels (Fig. 7E). A similar analysis 
carried out in the subgroup of the living breast cancer patients 
at stage 2 exhibiting high PDIA1 and low HLA-G mRNA 
levels indicated that longer survival was associated mainly 
with high PDIA1 and low HLA‑G mRNA levels in the 
ERα-negative patients (Fig. 7F) but there was no correlation in 
the ERα-positive patients (Fig. 7C).
Discussion
Protein disulfide isomerases compose a superfamily of more 
than 20 members of endoplasmic reticulum proteins that 
apart from protein folding exert multiple other functions 
including oxidoreductase activity, molecular chaperoning and 
acting as hormone reservoirs (10). The prototype member of 
the family PDIA1 is localized primarily in the endoplasmic 
Table I. Breast cancer patient data obtained from the METABRIC microarray dataset categorized by ERα status, stage of the 
disease and levels of PDIA1 and HLA-G mRNA expression levels. 
METABRIC
ERα-positive  Not known  378 1,457
 Stage 1 Low PDIA1 Low HLA-G 265
   High HLA-G 59
  HighPDIA1 Low HLA-G 48
   High HLA-G 15
 Stage 2 Low PDIA1 Low HLA-G 399
   High HLA-G 86
  HighPDIA1 Low HLA-G 92
   High HLA-G 38
 Stage 3 Low PDIA1 Low HLA-G 38
   High HLA-G 15
  HighPDIA1 Low HLA-G 14
   High HLA-G 1
 Stage 4 Low PDIA1 Low HLA-G 6
   High HLA-G 1
  HighPDIA1 Low HLA-G 2
   High HLA-G 0
ERα-negative  Not known  123 443
 Stage 1 Low PDIA1 Low HLA-G 27
   High HLA-G 24
  HighPDIA1 Low HLA-G 21
   High HLA-G 16
 Stage 2 Low PDIA1 Low HLA-G 45
   High HLA-G 57
  HighPDIA1 Low HLA-G 51
   High HLA-G 32
 Stage 3 Low PDIA1 Low HLA-G 18
   High HLA-G 13
  HighPDIA1 Low HLA-G 10
   High HLA-G 6
 Stage 4 Low PDIA1 Low HLA-G 0
   High HLA-G 0
  HighPDIA1 Low HLA-G 0
   High HLA-G 0
Total      1,900
ERα-positive or -negative breast cancer patients in stages 1-4 expressing high or low PDIA1 and HLA-G mRNA levels.
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reticulum but nuclear, mitochondrial and localization on the 
surface of the cellular membrane has also been reported (43). 
PDIA1 exerts tumor-stimulating or suppressing effects being 
involved in a wide spectrum of physiological functions in a 
manner dependent on the type of tissue, microenvironmental 
conditions, subcellular localization and its oxidized or reduced 
conformation (10-12). To shed light on the role of the PDIA1 in 
breast carcinogenesis we followed a variety of ROS modulated 
pathways in the estrogen receptor positive MCF-7 and the 
ERα negative MDA-MB-231 cells under differential oxidative 
stress conditions in the presence or absence of PDIA1.
In the present study, IFN-γ treatment reduced ROS levels 
in both MCF-7 and MDA-MB-231 cells whereas ETOP did 
not affect ROS generation in these cells in the presence of 
PDIA1. In the absence of PDIA1 IFN-γ treatment did not 
affect ROS levels in MCF-7 cells and increased oxidative 
stress in MDA-MB-231 cells. Estrogen receptor alpha (ERα) 
and estrogen receptor beta (ERβ) associate with IFN-γ and 
this association modulates malignant behaviour (53). In addi-
tion, PDIA1 interacts with ERα and regulates its structure 
and activity (54). Therefore the difference of the redox state 
between MCF-7 and MDA-MB-231 cells treated with IFN-γ 
could be attributed to the fact that MCF-7 cells are ERα and 
ERβ positive whereas MDA-MB-231 cells are triple negative 
breast cancer cells. PDIA1 functions as ERα coregulator 
modulating the receptor's transcriptional activity (54). ERα 
modulates the gene expression of growth hormone (GH) (55), 
which alters cellular oxidative stress levels (56). The differ-
ential regulation of the PDIA1-mediated GH gene expression 
in the ERα-positive MCF-7 cells and the ERα-negative 
MDA-MB-231 cells is an additional potential explanation 
justifying the differential redox state in the ERα positive vs. 
the ERα negative breast cancer cells. 
ETOP treatment, on the other hand, inhibited ROS 
generation in MCF-7 cells and induced oxidative stress in 
MDA-MB-231 cells in the absence of PDIA1 suggesting 
that this topoisomerase II inhibitor exerts its effects through 
distinct pathways in the two cell lines. ETOP induces stabi-
lization of the tumor suppressor p53 and PDI modifies the 
activity of this tumor suppressor (7) providing a potential 
explanation for the observed differences in ROS generation 
between the wild-type p53 expressing MCF-7 cells and the 
MDA-MB-231 cells which bear mutated p53 (p53-R280K). 
The gene expression of the NADPH oxidase family member 
Nox4, which is a source of ROS, has been demonstrated to be 
differentially regulated by wt and mutant p53 (57). Evidence 
indicating association between PDI and p53 (7) as well as 
PDI and Nox4 (58) has been previously presented suggesting 
that differences in the ROS levels generated in the MCF-7 
compared to MDA-MB-231 could be attributed to the differ-
ential Nox4 levels in the two cell lines. 
Glutathione is a known modulator of the function of 
PDIA1 (59) regulating the ratio of the oxidized vs. the reduced 
PDIA1 conformations (60). Oxidized and reduced PDIA1 
Figure 7. Kaplan-Meir survival curves showing the association of PDIA1 / HLA-G mRNA ratios with overall survival of stage 2 breast cancer patients. 
(A and D) Kaplan-Meir survival curves depicting the association between low PDIA1/high HLA-G and high PDIA1/low HLA-G mRNA ratios with overall 
survival of stage 2 ERα positive (A) and ERα negative (D) breast cancer patients. (B and E) Bar charts indicating the PDIA1/HLA‑G mRNA ratio in the ERα 
positive (B) and ERα negative (E) patients exhibiting low PDIA1/high HLA‑G mRNA ratio. (C and F) Bar charts indicating the PDIA1/HLA‑G mRNA ratio 
in the ERα positive (C) and ERα negative (F) patients exhibiting high PDIA1/low HLA‑G mRNA ratio. *P<0.05.
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conformations or death outcome during ER stress (9) suggest 
the importance of the interplay between GSH and PDIA1 in 
cancer progression. Silencing of PDIA1 increased cellular 
GSH concentration in MCF-7 cells whereas the opposite 
was the case in MDA-MB-231 cells where in the absence of 
PDIA1 decreased GSH levels were observed. Since depletion 
of cellular GSH is an indicator of apoptosis initiation (61), 
the obtained results indicate that PDIA1 is a pro-apoptotic 
factor in MCF-7 cells whereas in MDA-MB-231 cells it 
plays a pro-survival role. This conclusion is supported by 
the results obtained from the experiments assessing MOMP 
demonstrating that silencing of PDIA1 reduced the polariza-
tion of the mitochondrial membrane in untreated MCF-7 cells 
and did not affect mitochondrial membrane disruption in the 
MDA-MB-231 cells under the same conditions. A potential 
mechanism justifying the differential effects of PDIA1 
silencing on mitochondrial membrane potential in the two cell 
lines is the mitochondrial colocalization of the PDIA1 (13) 
with the estrogen receptors ERα and ERβ in the MCF-7 breast 
cancer cells (62). Mitochondrial localization of ERα is asso-
ciated with the modulation of the mitochondrial membrane 
potential and the inhibition of mitochondrial ROS generation 
due to the upregulation of the manganese superoxide dismutase 
activity in MCF-7 ERα-positive cells (62). 
The observed changes in the ROS generation, regulation 
of antioxidant cellular levels and mitochondrial membrane 
potential in the presence vs. the absence of PDIA1 are indica-
tions that PDIA1 plays a critical role in the communication 
between endoplasmic reticulum and mitochondria and as such 
in the regulation of mitochondrial biogenesis and potentially 
energy metabolism (63). Support to this hypothesis is lent 
by observations showing the relationship between calcium 
and energy metabolism and the link between PDIA1 and 
the regulation of calcium homeostasis (64). Measurement of 
ATP production indicated that MCF-7 cells produced higher 
ATP levels in the absence of PDIA1 whereas MDA-MB-231 
in the absence of PDIA1 produced significantly lower ATP 
levels. The crosstalk between PDIA1, p53 and Nox4 in the 
regulation of the activity of the mitochondrial respiratory 
chain (65,66) and thus ATP production may be the reason 
for the differential ATP levels observed in the MCF-7 and 
MDA-MB-231 cells.
The immune system recognizes and eliminates neoplastic 
cells by identifying tumor specific antigens presented to the 
immune system cells in complex with MHC class I molecules. 
The cellular redox state is a crucial factor contributing to 
the efficient recognition of tumor antigens by the immune 
system (25) and PDIA1 governs the antigen processing and 
presentation events (22). Apart from its role in the stabiliza-
tion of the early MHC class I complex and selection of the 
appropriate antigen PDIA1 has also been shown to participate 
in the regulation of the expression of the MHC class I (46). 
The expression of the classical or non-classical type of MHC 
class I is a critical point distinguishing the visible from the 
invisible to the immune system tumors, as overexpression of 
HLA‑G facilitates evasion of the immune surveillance by the 
tumor cells (50,67). HLA-G has been shown to inactivate the 
effector function of the natural killer (NK) cells by associating 
with the inhibitory receptor of these cells (51). Results shown 
in Fig. 6 indicate that the HLA-G cell surface levels in the 
cells expressing PDIA1 are higher compared to those in cells 
in which the expression of PDIA1 had been silenced implying 
that by regulating the HLA-G surface levels PDIA1 poten-
tially facilitates tumor cells to escape NK cell mediated innate 
immune responses thereby promoting immunotolerance (52). 
PDIA1 overexpression has been reported in several types 
of cancer and is correlated with metastasis and resistance to 
cancer therapy (68,69). PDIA1 has also been shown to asso-
ciate with well-characterized metastatic factors including 
metalloproteases, selectins and integrins (68,70). Results 
shown in this study indicating correlation between the 
PDIA1/HLA‑G mRNA ratio and overall survival in breast 
cancer patients provides further support for the hypothesis that 
PDIA1 is involved in the co-ordination of immune responses 
to tumor cells as well as in metastasis. Furthermore, the fact 
that high PDIA1 and low HLA‑G mRNA ratio was found in 
the subgroup of the stage 2 ERα-positive breast cancer patients 
exhibiting low PDIA1 and high HLA-G mRNA levels the 
longer they survive, whereas low PDIA1 and high HLA‑G 
mRNA ratio was measured in the longer survivors of the same 
subgroup of ERα-negative breast cancer patients could provide 
the potential means for selective treatment of the two different 
types of patients. 
PDIA1 plays differential role in the regulation of the 
cellular redox state in the ERα-positive MCF-7 vs. the TNBC 
MDA-MB-231 cells. In particular, silencing of PDIA1 down-
regulated ROS levels in MCF-7 cells and upregulated ROS 
levels in MDA-MB-231 cells. Upregulation of GSH levels 
in PDIA1 silenced MCF-7 cells and downregulation of GSH 
levels in PDIA1 silenced MDA-MB-231 cells suggesting that 
PDIA1 is a pro-apoptotic factor in the former and pro-survival 
in the latter cells. ATP production was not affected in 
MCF-7 cells whereas MDA-MB-231 cells in which PDIA1 
had been silenced produced lower ATP levels compared to 
PDIA1 expressing cells. The positive correlation of PDIA1 
mRNA levels with HLA‑G gene expression in breast cancer 
patients together with results showing downregulation of 
HLA-G levels on the extracellular membrane of MCF-7 and 
MDA-MB-231 cells lacking PDIA1 suggest that PDIA1 may 
contribute to the evasion of the immune surveillance by breast 
cancer cells. In addition the correlation of the ratio of PDIA1 
and HLA‑G mRNA levels in stage 2 breast cancer patients 
indicates that PDIA1 could be used as a determining factor 
in the stratification of patients that would be responsive to 
immunotherapy. 
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